| Identification | More | [Name]
Sermorelin | [CAS]
86168-78-7 | [Synonyms]
GHRF (1-29), AMIDE, HUMAN
GRF (1-29) AMIDE (HUMAN)
GROWTH HORMONE RELEASING FACTOR (1-29), AMIDE, HUMAN
GROWTH HORMONE RELEASING FACTOR, FRAGMENT 1-29 AMIDE
GROWTH HORMONE RELEASING FACTOR FRAGMENT 1-29 AMIDE HUMAN
H-TYR-ALA-ASP-ALA-ILE-PHE-THR-ASN-SER-TYR-ARG-LYS-VAL-LEU-GLY-GLN-LEU-SER-ALA-ARG-LYS-LEU-LEU-GLN-ASP-ILE-MET-SER-ARG-NH2
SERMORELIN
SERMORELIN ACETATE
TYR-ALA-ASP-ALA-ILE-PHE-THR-ASN-SER-TYR-ARG-LYS-VAL-LEU-GLY-GLN-LEU-SER-ALA-ARG-LYS-LEU-LEU-GLN-ASP-ILE-MET-SER-ARG-NH2
TYR-ALA-ASP-ALA-ILE-PHE-THR-ASN-SER-TYR-ARG-LYS-VAL-LEU-GLY-GLN-LEU-SER-ALA-ARG-LYS-LEU-LEU-GLN-ASP-ILE-MET-SER-ARG-NH2 HUMAN
YADAIFTNSYRKVLGQLSARKLLQDIMSR-NH2
growth hormone releasing factor*fragment 1-29 ami
Green tea powdered extract
SERMORELIN, GROWTH HORMONE RELEASING FACTOR FRAGMENT 1-29 AMIDE
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Thr-Arg-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH{2}
1-29-SOMATOLIBERIN (HUMAN PANCREATIC ISLET), 29-L-ARGININAMIDE-
somatoliberin fragment 1-29 amide, human | [EINECS(EC#)]
1312995-182-4 | [Molecular Formula]
C149H246N44O42S | [MDL Number]
MFCD00076559 | [Molecular Weight]
3357.88 | [MOL File]
86168-78-7.mol |
| Chemical Properties | Back Directory | [Melting point ]
>189°C (dec.) | [alpha ]
D20 -63.1° (c = 1 in 30% acetic acid) | [density ]
1.45±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C
| [solubility ]
Acetic Acid (Slightly), Trifluoroacetic Acid (Slightly), Water (Slightly) | [form ]
Solid | [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChIKey]
BVLCEKWPOSAKSZ-YQMCHIOTSA-N | [CAS DataBase Reference]
86168-78-7(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
Sermorelin is licensed as a diagnostic test for secretion of growth hormone. It is also used for the treatment of growth hormone deficiency in children. However, products containing sermorelin were withdrawn from the United States market by the manufacturer in November 2002. | [Uses]
xanthine oxidase inhibitor | [Definition]
Sermorelin is an analogue of growth hormone-releasing hormone (GHRH) primarily used for diagnostic purposes. It is a 29-amino acid-containing fragment of endogenous human GHRH, also represented as GHRH (1–29). Sermorelin is the shortest fully functional synthetic fragment of GHRH. It was marketed under the trade name of Geref by Serono Laboratories, but the FDA recently listed it as a “discontinued drug product.” | [Brand name]
Geref,Gerel
| [benefits]
The benefits of serotonin include: Improved body composition, muscle function, and strength; Faster and efficient healing of wounds; Reduced body fat, especially abdominal fat; Enhanced immune system, bone health, and cardiovascular function; Improved sleep quality, mood, and mental clarity. | [Mechanism of action]
Sermorelin binds to the growth hormone-releasing hormone receptor (GHRH), mimicking the effects of the full-length GHRH in promoting growth hormone secretion.
| [Side effects]
The most common side effect of sermorelin is caused by its injection under your skin. You may experience any of the following at the site of injection:
irritation
itching
sensitivity
swelling
pain
redness
| [Synthesis]
Sermorelin is prepared by solid-phase peptide synthesis. Step 1: Synthesis is performed on a 100 μmol scale. Amino acids with N-terminal Fmoc protection and side-chain protection are coupled sequentially according to the peptide sequence, using HBTU and D | [Drug interactions]
Sermorelin may interact with other medications. Drug interactions that may interfere with sermorelin include:
thyroid medications (levothyroxine)
cyclooxygenase inhibitors (aspirin)
glucocorticoids (prednisone)
insulin
muscarinic antagonists (atropine)
somatostatin-containing drugs or drugs that affect somatostatin (levodopa)
|
|
|